<DOC>
	<DOC>NCT01116440</DOC>
	<brief_summary>The purpose of this study is to determine efficacy, safety, tolerability and pharmacokinetics of multiple doses of BGS649 with concurrent daily administration of combined oral contraception in patients with refractory endometriosis</brief_summary>
	<brief_title>A Safety &amp; Efficacy Study of BGS649 in Women With Refractory Endometriosis</brief_title>
	<detailed_description />
	<mesh_term>Endometriosis</mesh_term>
	<mesh_term>Pelvic Pain</mesh_term>
	<criteria>Must have surgical diagnosis of endometriosis est. w/in 5 years before screening. Subjects must have self reported moderate to severe pelvic pain at screening to be confirmed during the runinphase Subjects with moderate to severe pelvic pain who were refractory to surgery (persistent or recurrent pelvic pain within 24 months after any therapeutic surgery) and at least two hormonal therapies from two different classes, including one approved hormonal therapy Subjects who have undergone hysterectomy or bilateral oophorectomy. Surgical treatment of endometriosis within 3 months before screening. Subjects who are pregnant or who were pregnant within 3 months of visit one. Subjects who are nursing or lactating Subjects who are tobacco smokers. Other protocoldefined inclusion/exclusion criteria may apply</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>49 Years</maximum_age>
	<verification_date>July 2011</verification_date>
	<keyword>Menstrual pain</keyword>
	<keyword>Refractory endometriosis</keyword>
	<keyword>Pelvic pain</keyword>
</DOC>